Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

24.75 -0.02 (-0.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 439,064
Open 24.97
Bid (Size) 24.52 (1)
Ask (Size) 24.99 (1)
Prev. Close 24.77
Today's Range 24.50 - 25.20
52wk Range 21.07 - 31.87
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its  
Via Benzinga

Performance

YTD
-10.10%
-10.10%
1 Month
-8.37%
-8.37%
3 Month
-9.84%
-9.84%
6 Month
+9.76%
+9.76%
1 Year
-15.76%
-15.76%

More News

Read More
Why Shares of Schrödinger Rose This Week
Via The Motley Fool
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
7 Biotech Stocks to Buy for 100% Returns
Via InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
Via InvestorPlace
Agios Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Looking Into Agios Pharmaceuticals Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
Via The Motley Fool
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Via Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Via Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Agios Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Via Benzinga
U.S. Stock Futures Higher; All Eyes On Inflation Data
Via Benzinga
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.